alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Status of Brookha

National Lab SEC Site Profile Issues Josie Beach, WG Chair Henry A. Anderson, M.D.Brad Clawson Wanda I. Munn Genevieve S. Roessler, P
Status: SEC Issues

 SEC’s approved for all BNL employees under §8

1947–1979, 1980–1993 based on lack of adequinternal dose records. 

 WG focus turned to validating “end-date” of SEC 

concern over inadequate records; SC&A evaluasample claimant cases to evaluate data adequa

 WG closed out issue following NIOSH substanti

data adequacy for 5 sample cases. 

 WG closed out remaining SEC issues with NIOS

verification of BNL electronic database (March 2ABRWH meeting). 
Status: Site Profile Issues

1. Bioassay Monitoring Not Adequately Established – clos2. Records of Bioassay Monitoring Not Centralized or Kno

Complete – closed 

3. Minimum Detectable Activity and Uncertainty Values No

Sufficiently Defined – recommend closure 

4. Radionuclide Characteristics Not Sufficiently Known – 

recommend closure 

5. No Internal Coworker Dose Database Available – close6. NTA Threshold Response Not Sufficiently Investigated 7. NTA Track Fading Not Covered in the Site Profile – rec

closure 

8. NTA/TLD/Lexan/CR-39 Problems need addressed – re

closure 
Status: Site Profile Issues (co

9. Potential Exposures at Accelerators Not Sufficiently Co

recommend closure 

10. External Coworker Dose Data Not Addressed – recom

closure 

11. Incidents and Unanticipated Events Not Addressed – 

recommend closure 

12. Potential Environment Exposures from Igloo Area Not A

– recommend closure 

13. The Site Profile has Inadequately Characterized the Nu

Types of X-rays Received by BNL Employees in Early Y(3 items to be addressed)– Items 2 and 3 recommend 

Item 1 open 
Site Profile Issues: Summa

 NIOSH responded to SC&A updated issues  Resolution achieved on 11 of 13 issues, whic

either have been closed or awaiting closure WG. 

 Issue 6 (low-energy neutrons) is currently be

addressed by NIOSH. SC&A will review NIOrecommendations when they are made avail

 Issue 13 (medical x-rays), Item 3, is being 

corrected by the addition of appropriate text describing Table 3-4 in the revised BNL TBD
CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                            AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

       In connection with the Quarterly Report of Edgeworth Investments, Inc.
(the "Company") on Form 10-Q for three month period ended September 30, 2010
as filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, G.J. de Klerk, certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of my knowledge and belief:

       1.  The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

       2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: October 18, 2010

                                         By:  /s/ G.J. de Klerk
                                              -------------------------------
                                              G.J. de Klerk
                                              Chief Executive Officer and
                                              Chief Financial Officer
                                              (Principal Executive Officer)
                                              (Principal Financial Officer)
II 

Calendar No. 551 

115TH CONGRESS 

2D SESSION H. R. 5772 

IN THE SENATE OF THE UNITED STATES 

JULY 17, 2018 

Received; read twice and referred to the Committee on Environment and 

Public Works 

AUGUST 1, 2018 

Reported by Mr. BARRASSO, without amendment 

AN ACT 

To designate the J. Marvin Jones Federal Building and 

Courthouse in Amarillo, Texas, as the ‘‘J. Marvin Jones 

Federal Building and Mary Lou Robinson United States 

Courthouse’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. DESIGNATION. 

4 The J. Marvin Jones Federal Building and Court5 house located at 205 SE 5th Ave., Amarillo, Texas, shall 

6 be known and designated as the ‘‘J. Marvin Jones Federal 

7 Building and Mary Lou Robinson United States Court8 house’’. 


daltland on DSKBBV9HB2PROD with BILLS
2 

•HR 5772 RS

1 SEC. 2. REFERENCES. 

2 Any reference in a law, map, regulation, document, 

3 paper, or other record of the United States to the Federal 

4 building and United States courthouse referred to in sec5 tion 1 shall be deemed to be a reference to the ‘‘J. Marvin 

6 Jones Federal Building and Mary Lou Robinson United 

7 States Courthouse’’. 


daltland on DSKBBV9HB2PROD with BILLS

daltland on DSKBBV9HB2PROD with BILLS
Calendar No. 551 

115TH CONGRESS 

2D SESSION H. R. 5772 

AN ACT 

To designate the J. Marvin Jones Federal Building 

Robinson United States Courthouse’’. Marvin Jones Federal Building and Mary Lou and Courthouse in Amarillo, Texas, as the ‘‘J. 

AUGUST 1, 2018 

Reported without amendment 


daltland on DSKBBV9HB2PROD with BILLS
AGENDA

Advisory Board on Radiation and Worker Health 

Teleconference Meeting of the 

Subcommittee on Procedures Review

November 20, 2017 

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

11:00 a.m. Eastern Time

Welcome and roll-call 

DISCUSSION

1. Administrative matters

2. Review of DCAS Program Evaluation Report 59: Norton Company, 

Worcester MA

3. Review of DCAS Report 5: Alternative Dissolution Models for Insoluble 

Plutonium 238

4. Review of ORAUT Report 78: Technical Basis for Sampling Plan

5. Review of Findings for Procedures: 22 (Supplemental Requests for DOE 

Information), 44 (Special Exposure Cohort), 86 (Case Preparation: 

Complex Internal Dosimetry Claims -- Cancelled), 94 (Verification and 

Validation Process for the Tools Development Group).

6. Priorities and timeline for completing consideration of outstanding 

findings. 

7. Identification of procedures not yet reviewed.

5:00 p.m. Adjourn
EXHIBIT 32.2





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Global Risk Management & Investigative Solutions (the “Company”) on Form 10-Q for the period ended September 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Maheu, Principal Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.











/s/ Peter Maheu


Peter Maheu


Principal Financial Officer


August 10, 2010
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I,  Andre Benard the Chief Executive Officer and Chief Financial Officer of Calibert Explorations Ltd.. (the Company), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (i)the Quarterly Report on Form 10-QSB of the Company, for the quarter  ended May 31, 2008, and to which this certification is attached as Exhibit 32 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(ii)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  By:/s/  Andre BenardName:Andre BenardTitle:Chief Executive Officer and ChiefFinancial OfficerDate:August 1, 2008 A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-QSB to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-QSB), irrespective of any general incorporation language contained in such filing.
ADVISORY BOARD ON RADIATION AND WORKER HEALTH
 

4676 Columbia Parkway, MS: C-46
 

Cincinnati, Ohio 45226
 

(513) 533-6825

CHAIRMAN

James M. Melius, M.D., Dr. PH.

Albany, New York

MEMBERS

Henry Anderson, M.D.

Madison, Wisconsin

Josie Beach

Kennewick, WaShington

Bradley P. Clawson

Rexburg, Idaho

R. William Field, Ph.D.

Iowa City, Iowa

Michael H. Gibson

Franklin, Ohio

Mark A. Griffon

Salem, New Hampshire

Richard Lemen, Ph.D.

Canton, Georgia

James E. Lockey, M.D.

Cincinnati, Ohio

Wanda I. Munn

Richland, Washington

John W. Poston, Sr., Ph.D.

College Station, Texas

Robert W. Presley

Seymour, Tennessee

David B. Richardson, Ph.D.

Chapel Hill, North Carolina

Genevieve S. Roessler, Ph.D.

Elysian, Minnesota

Phillip Schofield

Bosque Farm, New Mexico

Paul L. Ziemer, Ph.D.

Lafayette, Indiana

STAFF

EXECUnVESECRETARY

Theodore M. Katz, MPA

Atlanta, Georgia

COMMITTEE MANAGEMENT

Zaida Burgos

Atlanta, Georgia

November 3, 2010

The Honorable Pete Olson

United States House of Representatives

514 Cannon House Office Building

Washington, DC 20515

Dear Congressman Olson:

This letter is in response to your letter of October 1, 2010, inquiry to the

Advisory Board on Radiation and Worker Health (ABRWH) regarding the

Special Exposure Cohort (SEC) petition on the Texas City Chemicals site

submitted to the National Institute for Occupational Safety and Health

(NIOSH) under the Energy Employees Occupational Illness

Compensation Program Act of 2000 (EEOICPA). Under EEOICPA, the

ABRWH is responsible for reviewing NIOSH's evaluations of SEC

petition evaluations and making a recommendation to the Secretary of

the Department of Health and Human Services (HHS) on whether or not

the class under consideration should be added to the Special Exposure

Cohort.

NIOSH has revised its original evaluation report on the Texas City site

and provided it to the petitioners and the Board. This revision is in

response to concerns raised by the Board in its review of an evaluation

report for another SEC petition. The Board's work group responsible for

reviewing the report is meeting on November 5, 2010 to discuss the

NIOSH report prior to our November Board meeting. The full Board

plans to discuss the Texas City report at our mid November Board

meeting in Santa Fe, New Mexico. I expect that the Board will be able to

make a recommendation to the Secretary regarding the Texas City site at

this November Board meeting.

The Board appreciates your interest and concerns about this matter. If

we can provide any further assistance, please contact us.
Page 2

Thank you for your continued interest in the Energy Employees Occupational Illness

Compensation Program Act (EEOICPA) and the activities of this Board.

Sincerely,

James M. Melius, M.D., Dr. Ph.

Chairman, Advisory Board on Radiation and

Worker Health
[Federal Register Volume 73, Number 22 (Friday, February 1, 2008)]
[Notices]
[Pages 6192-6193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-437]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Child Health and Human Development; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Health, Behavior, and Context 
Subcommittee.
    Date: February 29, 2008.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ramada Inn Rockville, 1775 Rockville Pike, Rockville, MD 
20852.
    Contact Person: Michele C. Hindi-Alexander, PhD, Division of 
Scientific Review, National Institutes of Health, National Institute 
for Child Health and Human Development, 6100 Executive Boulevard, 
Room 5B01, Bethesda, MD 20812-7510, (301) 435-8382, 
<a href="/cdn-cgi/l/email-protection#95fdfcfbf1fcf4f9f8d5f8f4fcf9bbfbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="7e1617101a171f12133e131f17125010171650191108">[email protected]</span></a>.


[[Page 6193]]


(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-437 Filed 1-31-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Heart, Lung, and Blood Initial Review Group, Clinical Trials Review Committee.                    

*Date:*                         February 25-26, 2008.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         InterContinental Harbor Court/Baltimore, 550 Light Street, Baltimore, MD 21202.                    

*Contact Person:*                         Patricia A. Haggerty, PhD, Section Chief, Clinical Studies and Training Scientific Review Group, Review Branch, Division of Extramural Research Activities, National Heart, Lung, and Blood Institute, NIH, 6701 Rockledge Drive, Room 7194, MSC 7924, Bethesda, MD 20892, 301/435-0288,                         *haggertp@nhlbi.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

      ( print page 5860)    
Dated: January 24, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 08-420 Filed 1-30-08; 8:45 am]

BILLING CODE 4140-01-M
AGENDA

Advisory Board on Radiation and Worker Health 

Meeting of the

Savannah River Site Work Group

February 3, 2011

Cincinnati Airport Marriott 

2395 Progress Dr. 

Hebron, KY 41048 

859-586-0166

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

9:00 a.m. Welcome and roll-call/introductions 

WG Discussion

1. Discuss open SEC petition issues

• Matrix Issue 1: Thorium-232 dose reconstruction model for 1953-1965; SC&A present 

its Review and DCAS provide initial response

• Matrix Issue 2: Thorium (oxide) after 1964; DCAS present response to SC&A report, 

reprocessing, and other issues not covered in ORAU report 0046. 

• Matrix Issue 3: Recycled Uranium; SC&A present review of DCAS July 2010 update. 

• Matrix Issue 4: Dose reconstruction data for fission fragments: DCAS will develop

coworker model addressing data adequacy for Am, Cm, Cf, including CW vs. NCW 

issue. Matrix Issue 9 -- Tritium coworker model to be addressed first – this should 

indicate path forward. 

• Matrix Issue 5-7: Other radionuclides; same path forward as Issue 4 above.

• Matrix Issue 8: Coworker model for Polonium: DCAS summarize report under review. 

• Matrix Issue 9: Tritium coworker model: SC&A present Review and DCAS report 

initial response, DCAS summarize soon to be released report “coworker part 2” 

• Matrix Issue 10: Dose reconstructions for tritides: SC&A and DCAS report status of 

providing interview summaries and notes. 

• Matrix Issue 11: Dose reconstruction approach for “exotic” radionuclides: General issue 

being addressed by Board; SC&A present memorandum identifying radionuclides in use 

at SRS and not already addressed under other matrix issues, DCAS report initial 

response. 

• Matrix Issue 12: Internal dose incidents: SC&A present memorandum on incidents not 

covered by Site Profile Special Hazards Investigation Index; DCAS report initial 

response. 

• Matrix Issue13: Relationship between CW and NCW internal doses/OTIB 52; DCAS 

report status of OTIB revision. SC&A will review it. 
• Matrix Issue 14: Open pan burning of contaminated solvents: DCAS report status of draft 

report addressing internal dose; external dose to be addressed under Issue 20. 

• Matrix Issues 15-16: Use of adjustment factors for CW exposures: SC&A report -- See 

Issue 9.

• Matrix Issue 17: Neutron dose reconstruction up to 1961: DCAS report status. 

• Matrix Issue 18: Neutron dose reconstruction from 1962-1971: DCAS report status. 

• Matrix Issue 20: Exposure geometry in tank farm: DCAS report status, SC&A provide 

documents on this geometry. 

• Matrix Issues 22-23: External dose reconstruction issues of petitioners: SC&A present 

report and DCAS report initial response. 

2. Recap current action items and discuss timeframe

3. Schedule next work group meeting if feasible

Adjourn
Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

iGATE Corporation

Pittsburgh, Pennsylvania

We hereby consent to the
incorporation by reference in the Registration Statements on Form S-3 (No. 333-33604, 333-37770, 333-73365 and 333-58217) and Form S-8 (No. 333-20043, 333-71057 and 333-134689) of iGATE Corporation of our reports dated March 17, 2008,
relating to the Consolidated Financial Statements and financial statement schedule, and the effectiveness of iGATE Corporations internal control over financial reporting, which appear in this Form 10-K.



|                      
|----------------------
|/s/    BDO SEIDMAN LLP
|                      
|Milwaukee, Wisconsin  
|March 17, 2008
AGENDA

Advisory Board on Radiation and Worker Health Teleconference of the

Subcommittee for Procedure Reviews (SCPR)

May 25, 2022

Conference Call Number: 1-866-659-0537; Participant Passcode: 9933701

11:00 a.m. (Eastern Time) Welcome and roll-call/introductions

Carryover items from Feb 15, 2022 SCPR meeting; Newly-issued SC&A reviews:

1. DCAS-PER-052, Subtask 4 “Westinghouse Nuclear Fuels Division” case reviews

2. DCAS-PER-059, Subtask 4 “Norton Company” case review

3. DCAS-PER-062, Subtask 4 “ORAUT-OTIB-0052 Parameters to Consider When Processing 

Claims for Construction Trade Workers” case review

Document tracking

Preparation for August 2022 Full ABRWH Meeting: Review of technical guidance documents ready for full 

Board approval

Newly-Issued Guidance Documents and Supplemental Topics

Next SC Meeting/Plans

3:30 p.m. Adjourn
### **EXHIBIT 13 
Sharpe Resources Corporation 
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Roland M. Larsen, Chief Executive Officer of Sharpe Resources Corporation("the Company"), certify that:- the annual report on Form 20F of the Company for the fiscal year ending December 31,    2009 as filed with the Securities and Exchange Commission on the date hereof (the    "report") fully complies with the requirements of Section 13(a) or 15(d) of the    Securities and Exchange Act of 1934; and 
- the information contained in the Report fairly presents, in all material respects, the    financial condition and results of operations of the Company. 

/s/ Roland M. Larsen Roland M. Larsen Chief Executive Officer June 29, 2010 

**Sharpe Resources Corporation Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Kimberly L. Koerner, Director of Sharpe Resources Corporation ("theCompany"), certify that:- the annual report on Form 20F of the Company for the fiscal year ending December 31,    2009 as filed with the Securities and Exchange Commission on the date hereof (the    "report") fully complies with the requirements of Section 13(a) or 15(d) of the    Securities and Exchange Act of 1934; and 
- the information contained in the Report fairly presents, in all material respects, the    financial condition and results of operations of the Company. 

/s/ Kimberly L. Koerner Kimberly L. Koerner Director June 29, 2010 

**Sharpe Resources Corporation Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Troy Koerner, Director of Sharpe Resources Corporation ("theCompany"), certify that:- the annual report on Form 20F of the Company for the fiscal year ending December 31,    2009 as filed with the Securities and Exchange Commission on the date hereof (the    "report") fully complies with the requirements of Section 13(a) or 15(d) of the    Securities and Exchange Act of 1934; and 
- the information contained in the Report fairly presents, in all material respects, the    financial condition and results of operations of the Company. 

/s/ Troy Koerner Troy Koerner Director June 29, 2010******